Debin Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Debin Ma has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Erguang Liang
Institute of Toxicology and Pharmacology, Medicine Military Medical Science Academy of the Chinese PLA, Beijing 100850, China
2 shared publications - Fan Feng
Department of Laboratory Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, the People's Republic of China
2 shared publications - Guofu Dong
Basic Medical College of Anhui Medical University
2 shared publications - Hui Jia
Department of Pharmacy, General Hospital of Shenyang Military Command, Shenyang 110016, China
2 shared publications - Mengmeng Qin
Department of Respiratory Diseases, General Hospital of Shenyang Military Command, Shenyang 110016, China
2 shared publications - Tao Wang
Institute of Toxicology and Pharmacology, Medicine Military Medical Science Academy of the Chinese PLA, Beijing 100850, China
2 shared publications
Latest Publications
- Open Access
- 14 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1614
RETRACTED: Ma et al. MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line. Int. J. Mol. Sci. 2015, 16, 22137–22150
The Journal retracts the article “MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line”
- 14 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1614
Open AccessRETRACTED: Ma et al. MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line. Int. J. Mol. Sci. 2015, 16, 22137–22150
The Journal retracts the article “MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line”
- Open Access
- 14 September 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (9) , 22137-22150
RETRACTED: MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line
MiR-122 is a novel tumor suppresser and its expression induces cell cycle arrest, or apoptosis, and inhibits cell proliferation in multiple cancer cells, including non-small cell lung cancer (NSCLC) cells. Radioresistance of cancer cell leads to the major drawback of radiotherapy for NSCLC and the induction of radiosensitization could be a useful strategy to fix this problem. The present work investigates the function of miR-122 in inducing radiosensitization in A549 cell, a type of NSCLC cells. MiR-122 induces the radiosensitization of A549 cells. MiR-122 also boosts the inhibitory activity of ionizing radiation (IR) on cancer cell anchor-independent growth and invasion. Moreover, miR-122 reduced the expression of its targeted genes related to tumor-survival or cellular stress response. These results indicate that miR-122 would be a novel strategy for NSCLC radiation-therapy.
- 14 September 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (9) , 22137-22150
Open AccessRETRACTED: MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line
MiR-122 is a novel tumor suppresser and its expression induces cell cycle arrest, or apoptosis, and inhibits cell proliferation in multiple cancer cells, including non-small cell lung cancer (NSCLC) cells. Radioresistance of cancer cell leads to the major drawback of radiotherapy for NSCLC and the induction of radiosensitization could be a useful strategy to fix this problem. The present work investigates the function of miR-122 in inducing radiosensitization in A549 cell, a type of NSCLC cells. MiR-122 induces the radiosensitization of A549 cells. MiR-122 also boosts the inhibitory activity of ionizing radiation (IR) on cancer cell anchor-independent growth and invasion. Moreover, miR-122 reduced the expression of its targeted genes related to tumor-survival or cellular stress response. These results indicate that miR-122 would be a novel strategy for NSCLC radiation-therapy.